3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management

Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management

Primary Versus Secondary Dysmenorrhea

Dysmenorrhea refers to painful, cramping pelvic discomfort associated with menstruation. Clinically, it is classified into primary or secondary etiologies:

Pathophysiology of Primary Dysmenorrhea

Progesterone withdrawal at the end of the luteal phase triggers lysosomal enzyme release, mobilizing arachidonic acid and stimulating cyclooxygenase (COX) to produce high levels of prostaglandin F2-alpha (PGF2-alpha). PGF2-alpha causes potent myometrial vasoconstriction and uncoordinated, high-pressure uterine contractions exceeding 100 to 120 mmHg (surpassing uterine arterial pressure). This induces transient myometrial ischemia, anaerobic metabolite accumulation, and activation of pelvic nociceptive fibers.

First-Line Pharmacotherapy for Primary Dysmenorrhea

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): First-line medical therapy. NSAIDs inhibit COX-1 and COX-2 enzymes, suppressing prostaglandin synthesis. To achieve maximal efficacy, NSAIDs must be initiated 1 to 2 days prior to anticipated menses or at the earliest sign of cramping, and taken on a scheduled basis for 48 to 72 hours. First-line agents include ibuprofen (600–800 mg PO every 8 hours) or naproxen sodium (550 mg loading dose, followed by 275 mg every 6 to 8 hours).
• Hormonal Contraceptives: For patients who fail NSAIDs, require contraception, or desire cycle control, combined hormonal contraceptives (pills, patch, vaginal ring) or progestin methods (52 mg levonorgestrel IUS, etonogestrel implant, DMPA) serve as first-line therapy by suppressing ovulation, reducing endometrial proliferation, and decreasing menstrual prostaglandin output.

Endometriosis: Pathogenesis, Presentation, and Staging

Endometriosis is an estrogen-dependent chronic condition defined by the presence of ectopic endometrial glands and stroma outside the uterine cavity. The primary pathogenic framework is Sampson's theory of retrograde menstruation, where sloughed menstrual tissue migrates through the fallopian tubes into the peritoneal cavity, implanting and inciting local inflammation, fibrosis, and adhesion formation.

Clinical Presentation

The hallmark presentation includes the "classic triad":

1. Secondary Dysmenorrhea: Severe, progressive cramping poorly responsive to standard analgesics.
2. Deep Dyspareunia: Sharp, deep pelvic pain during sexual penetration caused by traction on the uterosacral ligaments or the pouch of Douglas.
3. Dyschezia: Painful defecation, particularly during menses, reflecting rectovaginal septum involvement.

Other manifestations include subfertility (affecting 30% to 50% of patients due to anatomical distortion and peritoneal inflammatory toxicity), catamenial dysuria, and non-cyclical chronic pelvic pain.

Physical Examination Findings

Classic examination findings include:

• Exquisite focal tenderness and palpable nodularity along the uterosacral ligaments.
• A fixed, immobile, retroverted uterus held by fibrotic adhesions.
• Firm, tender nodules in the posterior vaginal fornix (occasionally visible as bluish implants on speculum exam).
• Tender, fixed adnexal fullness or mass indicative of an endometrioma ("chocolate cyst").

Diagnosis and Staging

Transvaginal ultrasound (TVUS) detects ovarian endometriomas (homogeneous, low-level, "ground-glass" internal echoes) and deep infiltrating disease, but has limited sensitivity for superficial peritoneal implants. The definitive gold standard for diagnosis is diagnostic laparoscopy with histologic biopsy confirming ectopic endometrial glands and stroma. ESHRE (2022), however, no longer requires laparoscopy before treatment: normal imaging does not exclude superficial disease, and empiric hormonal therapy is reasonable when symptoms fit.

The revised American Society for Reproductive Medicine (ASRM) classification stages disease from Stage I (minimal), Stage II (mild), Stage III (moderate), to Stage IV (severe):

Medical and Surgical Management of Endometriosis

Medical therapy suppresses ovarian estrogen production and induces atrophy of ectopic implants:

First-Line Medical Therapies

• Continuous Combined Oral Contraceptives (COCs): Continuous regimens without a placebo interval suppress ovulation and induce decidualization and atrophy of ectopic lesions.
• High-Dose Progestins:
  • Norethindrone acetate: 5 mg daily, titrated up to 15 mg daily to achieve amenorrhea.
  • Dienogest: 2 mg daily (marketed for endometriosis outside the United States), an oral progestin with selective anti-proliferative and anti-inflammatory activity against endometriotic implants.
  • Levonorgestrel 52 mg IUS: Significantly reduces dysmenorrhea and pelvic pain associated with peritoneal disease.

Second-Line Medical Therapies

• GnRH Agonists: Leuprolide acetate (3.75 mg monthly IM or 11.25 mg every 3 months). After a transient initial flare, continuous receptor stimulation downregulates pituitary GnRH receptors, inducing a hypoestrogenic state.
  • Add-Back Therapy: To prevent rapid bone mineral density (BMD) loss and severe vasomotor symptoms, mandatory add-back therapy with norethindrone acetate (5 mg daily) with or without low-dose estrogen must be co-prescribed.
• Oral GnRH Antagonists: Elagolix (150 mg daily for up to 24 months, or 200 mg twice daily for up to 6 months) and relugolix combination therapy competitively bind GnRH receptors, providing dose-dependent estradiol suppression without an initial hormonal flare.

Surgical Interventions

• Conservative Laparoscopy: Excision or ablation of visible implants, adhesiolysis, and ovarian cystectomy (excising the endometrioma capsule while preserving healthy ovarian cortex).
• Definitive Surgery: Total hysterectomy with bilateral salpingo-oophorectomy (BSO) for completed childbearing and refractory pain.

Chronic Pelvic Pain (CPP) & Multidisciplinary Evaluation

Chronic pelvic pain (ACOG Practice Bulletin 218) is cyclic or noncyclic pain perceived to originate from pelvic organs, localized to the anatomical pelvis, anterior abdominal wall at or below the umbilicus, lower back, or buttocks, persisting for at least 6 months, and causing functional disability.

CPP frequently involves overlapping non-gynecologic organ systems:

• Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS): Chronic suprapubic discomfort or bladder pressure associated with urgency and frequency, characteristically relieved by voiding.
• Irritable Bowel Syndrome (IBS): Recurrent abdominal pain associated with defecation and altered bowel habits, diagnosed using Rome IV criteria.
• Myofascial Pelvic Pain: Hypertonicity and trigger points in the levator ani and obturator internus muscles. Evaluated via internal pelvic floor muscle palpation. Carnett's sign (abdominal tenderness persisting or worsening when the patient tenses abdominal muscles) differentiates abdominal wall trigger points from visceral disease.
• Multidisciplinary Management: Specialized pelvic floor physical therapy (PFPT) focusing on relaxation, trigger point release, and down-training (avoiding Kegels in hypertonic floors); neuropathic agents (gabapentin, amitriptyline); and cognitive-behavioral therapy (CBT).